A protein once thought to simply help cancer cells avoid death turns out to do much more. MCL1 actively drives cancer ...

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. A phase I study of the oral mTOR ...

Aging-US Issue 1 Volume 13 features "PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging" which reported that despite a growing proportion of aged individuals at ...

Recombinant human ACE2 as a novel biotherapeutic for the treatment of patients with cancer. Background: EGFR-TKI is one of the most important treatments of NSCLC patients, but not all patients ...

Researchers have shown that the protein MCL1 not only inhibits programmed cell death, but also plays a central role in tumor ...